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Abstract
Background/Aims
Extraintestinal cutaneous manifestations of IBD represent a severe disease complication
and an early and accurate treatment might positively influence the disease course. Using
the patient collective of the Swiss IBD Cohort Study (SIBDCS), we analysed epidemiological
as well as clinical factors being associated with the onset of pyoderma gangrenosum, ery-
thema nodosum and aphthous ulcers in IBD patients.
Methods
We included 3266 SIBDCs patients, 1840 with Crohn’s disease (CD) and 1426 with ulcera-
tive colitis (UC) or IBD unclassified (IBDU) and analysed the association of cutaneous mani-
festations with age, age at diagnosis time, type of disease, gender, family history, HLA-
allotype, smoking, intestinal disease activity, therapy and other extraintestinal manifesta-
tions (EIM).
Results
354 CD patients and 136 UC/IBDU patients presented with skin manifestations at any time
during their disease course. In both, CD and UC, female gender and younger age at IBD
diagnosis were significantly associated with extraintestinal skin manifestations. For CD, we
also detected a positive family history as associated factor. As an indicator of more intensive
intestinal disease activity, patients with cutaneous manifestations of IBD needed more fre-
quently therapy with antibiotics, steroids, immunomodulators and anti-TNF. Multivariate
analysis revealed female gender, younger age at diagnosis and presence of other extrain-
testinal manifestations as factors being associated with skin EIM in IBD patients and anti-
TNF as well as immunomodulatory treatment in CD patients.
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Conclusion
Our results suggest that young females with a positive family history of IBD might be at
increased risk for the onset of skin manifestations and require a careful screening for such
complications.
Introduction
Inflammatory bowel disease (IBD) patients are commonly affected by extraintestinal manifes-
tations (EIM) affecting the joints, skin, eyes, and biliary ducts, the overall appearance ranges
from 6% to 47% [1–9] and up to 10% at the time of IBD diagnosis [10]. Peripheral arthritis,
erythema nodosum and aphtous ulcers are associated with the activity of the intestinal disease.
Other EIM, such as primary sclerosing cholangitis (PSC), pyoderma gangrenosum, uveitis and
spondylarthropathy, are considered independent from intestinal activity [1, 11–13]. We have
recently shown that in 25.8% of patients of the Swiss IBD Cohort Study (SIBDCS) EIM occur
even before IBD is diagnosed [14].
Previous studies showed that almost one quarter of patients with EIM present with a combi-
nation of several EIMs suggesting that the appearance of one EIM favours the onset of at least
one other EIM [15, 16]. In the SIBDCS this constellation occurred in 15% of Crohn’s disease
(CD) and 8% of ulcerative colitis (UC) patients [11]. Most patients with EIM present with a
severe colitis and some of them also reveal a positive family history for IBD [15, 17]. This
allows the assumption, that there is at least some genetic influence.
The inflamed intestinal mucosa may trigger an extraintestinal immune response due to spe-
cific epitopes that are detectable in, e.g. intestinal bacteria and synovia. The immune system is
incapable of distinguishing the two epitopes and therefore attacks both, as shown by Bhagat
et al. in 1994. They found an isoform of tropomysin, which is expressed in all the organs that
can be affected by EIM of IBD as well as in the gut and postulated an autoimmune reaction
towards this molecule as a cause of EIM in IBD patients [18]. Genetic factors may also critically
influence this particular immune reaction. EIM occur more often in people carrying specific
HLA-constellations, for example CD with HLA-A2, HLA-DR1 and HLA-DQw5; UC with
HLA-DR103 [19]. There are even specific HLA-types associated with certain EIM.
HLA-DRB1�0103, HLA-B�27 and HLA-B�58 are associated with erythema nodosum, spondy-
larthropathy and uveitis [20, 21]. One gene has already been associated with the risk of skin
manifestation in IBD patients, namely TRAF3IP2 [22]. Further hints that genetic factors may
influence the occurrence of erythema nodosum are provided by the fact that it is more fre-
quently found in CD and female patients [2, 11, 23, 24].
From a clinical point of view, it would be important to know the patient characteristics that
are associated with the onset of each single cutaneous manifestation in IBD patients. There-
fore, using the exclusive patient collective of the SIBDCS, we studied the correlation between
epidemiological and clinical factors and the development of erythema nodosum, pyoderma
gangrenosum or aphthous ulcers in IBD patients.
Patients and methods
Patient data
Data were retrieved from the nationwide Swiss Inflammatory Bowel Disease Cohort Study
(SIBDCS). The SIBDCS is a multicenter prospective observational population-based study and
IBD and skin manifestations
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includes patients with IBD from Switzerland. The study was implemented in all regions of
Switzerland in 2006 in a multidisciplinary effort by gastroenterologists, pathologists, psycholo-
gists and bioinformatics specialists. The cohort study is funded by the Swiss National Science
Foundation (SNSF). For inclusion in the SIBDCS, all patients must have a diagnosis estab-
lished at least 4 months prior to inclusion. Data are prospectively collected once a year and
entered into a central database. Inclusion and exclusion criteria are described elsewhere [25].
A total of 3266 patients were included in the current study of which 1840 suffered from CD
and 1426 from UC or IBDU. The last two were treated as one group.
Study design
We included all patients involved in the SIBDCS [suffering from either CD, UC or IBD unclas-
sified (IBDU) = indeterminate colitis (IC)] available in the cohort for our study and discrimi-
nated the patients into two groups, one group with skin manifestations (erythema nodosum,
pyoderma gangrenosum or aphthous ulcers) at inclusion or during any follow-up and another
group without skin manifestations at any time of their disease course. Only those three skin
EIM are mentioned in the SIBDC questionnaires and therefore considered for further analysis.
No other skin EIM, such as atopic dermatitis, were included in our analysis, since they would
not reflect a predefined answer in the SIBDCS questionnaires. The skin manifestations were
diagnosed by the treating physician who was usually a gastroenterologist. In case of uncertain-
ties, the patients had been sent to a dermatologist for final diagnosis. This means, mostly the
diagnosis has been made by clinical judgement rather than by a biopsy.
Patients with CD were considered as a single entity and patients with Crohn’s colitis and
Crohn’s ileitis were not distinguished. UC and IBDU were grouped together. Univariate and
multivariate logistic regression analyses were performed. The following possible explanatory
variables were considered: 1) Epidemiological characteristics: diagnosis of CD, UC or IBDU,
age, disease duration (years), gender, age at diagnosis and latest follow-up, body mass index
(BMI), smoking status and family history of IBD. 2) Disease characteristics and complications:
activity index, initial and current disease location, extra-intestinal manifestations (EIM), exis-
tence of CD-related complications such as stenosis, fistula, fissure, abscess, intestinal surgery,
anemia and vitamin B12 levels. 3) Selected medications: 5-ASA, antibiotics, steroids, immuno-
modulators (azathioprine, 6-mercaptopurin), anti-TNF antibodies and calcineurin inhibitors.
4) Genetic data for skin EIM in CD and UC patients. 5) Longitudinal data on skin EIM in CD
and UC patients.
Non-skin EIM included arthritis, uveitis/ iritis, ankylosing spondylitis and PSC. Malabsorp-
tion syndrome with consequent anemia and vitamin B12 deficiency was also considered as a
complication. To assess disease activity and allow comparison between UC (Modified True-
love and Witts activity index, MTWAI) and CD (Crohn’s disease activity index, CDAI), dis-
ease activity measures were normalized to a value between 0 and 100 and expressed as an
activity index. In particular, IBD medication was documented by the treating physician in the
specific SIBDC questionnaires at patient inclusion and follow-ups as well as by the patient
questionnaires.
Statistical analysis
All statistical analyses were carried out using the Stata Software (v. 14.2, StataCorp, College
Station, TX, USA) and the R software (v. 3.3.1, The R Foundation for Statistical Computing,
Vienna, Austria). Normal QQ-plots were used to assess distribution of continuous data.
Gaussian-distributed data were reported as mean, standard deviation and range, while non-
Gaussian data were presented as median, interquartile range and range. Differences in means
IBD and skin manifestations
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between two independent groups for Gaussian-distributed data were assessed using the Stu-
dent’s t-test. Differences in distribution locations between two independent groups for non-
Gaussian data were assessed using the Mann-Whitney-Wilcoxon ranksum test. Categorical
data were presented as raw frequencies and relative percentages. Differences in distributions
for categorical data between two or more groups were assessed using the Chi-square test, or
the Fisher’s exact test in case of insufficient sample size.
Time-to-event data were analysed using the Kaplan-Meier estimator, using specific tech-
niques to deal with interval-censored data. Results were presented as cumulative proportion
curves.
Multivariate logistic regression was used to assess the association of multiple factors with
the occurrence of skin EIM. First, all factors with univariate p-value < 0.200 were included
into the multivariate model. Non-significant factors (p>0.05) were then excluded from the
model one-by-one, until all remaining factors were significant. In a last step, all factors that
were left aside were once more inserted one-by-one into the model and kept if proven signifi-
cant, while checking for model consistency at each step of the procedure.
Ethical considerations
The IBD cohort study has been approved by the respective ethics committees in Switzerland
(Ethics Committee of the Canton Zu¨rich: EK-1316). All patients signed an informed consent
and confirmed their participation in the cohort study at the time of enrolment and gave
informed consent for data collection and analysis for research purposes. The current substudy
has been evaluated and approved by the scientific board of SIBDCS.
Results
Epidemiology of skin manifestations in SIBDCS patients
In our study, we analysed data from 3266 IBD patients, of whom 1840 suffered from CD and
1426 from UC/IBDU. Out of the 1840 CD patients, 354 (19.2%) patients suffered from skin
manifestations at any time during their disease course. Out of the 1426 UC/IBDU patients, 136
(9.5%) patients suffered from skin manifestations at any time during their disease course. For
both, CD and UC/IBDU patients, the median age at occurrence of the skin EIM was 39 years.
In 222 (62.7%) of the CD patients and in 94 (69.1%) of UC/IBDU patients, the skin EIM had
already occurred before inclusion into the SIBDCS. With respect to CD patients, 29 (1.6%) suf-
fered from pyoderma gangrenosum, 140 (7.6%) from erythema nodosum and 238 (12.9%)
from aphthous ulcers. With respect to UC/IBDU patients, 25 (1.8%) exhibited pyoderma gang-
renosum, 51 (3.6%) erythema nodosum and 77 (5.4%) aphthous ulcers (Table 1).
Disease characteristics, complications and skin manifestations in CD
patients
242 (68.4%) of CD patients were female, significantly more than male (112, 31.6%; (p =
<0.001). In the group without skin manifestations no difference between genders (51.5% male
vs. 48.5% female) was detected. Furthermore, those patients with skin manifestations were sig-
nificantly younger at CD diagnosis than those without skin manifestations (25.8 years vs. 27
years, p = 0.006). However, no significant difference in age at latest follow up, disease duration,
BMI or smoking status at diagnosis and latest follow-up was found between the two groups.
CD patients with skin manifestations at enrolment showed a significantly higher rate of posi-
tive family history for IBD (16.9% vs. 12.5%; p = 0.006). The family history of IBD was
IBD and skin manifestations
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unknown in 6.8% of patients with skin manifestations and 11.5% of patients without skin man-
ifestations (Table 2).
There was no significant difference in the initial disease location between patients who
developed skin manifestations and those who did not in the course of observation. During the
follow-up period a tendency towards a shift of the disease location from mainly in the ileoco-
lon (L3, 44.9% vs. 27.5% without skin EIM; 42.7% vs. 24.6% with skin EIM) towards the termi-
nal ileum (L1, 24.7% vs. 28.5 without skin EIM; 20.9% vs. 26.6% with skin EIM), colon only
(L2, 18.8% vs. 29.7% without skin EIM; 24.3% vs. 32.3% with skin EIM) and upper gastro
intestinal tract (L4, 0.7% vs. 2% without skin EIM; 0.9% vs. 4.5% with skin EIM) was detected.
Considering the CDAI at enrolment in the SCIBD, there was a significantly higher disease
activity in the patients group with vs. without skin manifestations (CDAI 51 vs. 31, p =
<0.001). This difference remained also significant at latest follow-up (CDAI 33 vs. 20, p =
<0.001) (Table 3).
Considering CD-related complications there was no difference between patients with or
without skin manifestation during observation period for perianal fistula, any other fistula,
abscess or stenosis. However, patients with initial skin manifestations suffered from a signifi-
cantly higher rate of abscesses (28.8% vs. 23.6%, p = 0.042). As for CD-related surgery no sig-
nificant difference for intestinal resection, fistula or surprisingly even abscess surgery (26% vs.
24.8%) could be detected. Although there was no significant difference between vitamin B12
levels (Median 252 pmol/l vs. 241 pmol/l), patients with skin manifestations tended to receive
vitamin B12 supplementation more often (56% vs. 49.8%, p = 0.052). As for anemia those
patients with skin manifestation developed significantly more anemia during SIBDCS follow
up (35.5% vs. 28.9%, p = 0.016). Nevertheless, at latest follow-up there was no longer any dif-
ference detectable (10.5% vs. 11.9%, p = 0.506) (Table 3).
Table 1. Skin manifestations (pyoderma gangrenosum, erythema nodosum, aphthous ulcers) in SIBDCS patients.
CD patients UC/IBDU patients
Skin EIM n = 1840 n = 1426
No 1486 (80.8) 1290 (90.5) 2776 (85.0)
Yes 354 (19.2) 136 (9.5) 490 (15.0)
Pyoderma gang. 29 (1.6) 25 81.8) 54 (1.7)
Erythema nod. 140 (7.6) 51 (3.6) 191 (5.9)
Aphtous ulcers 238 (12.9) 77 (5.4) 315 (9.6)
Pyoderma gang. Occurence
Before inclusion 20 (69.0) 20 (80.0) 40 (74.1)
After inclusion 9 (31.0) 5 (20.0) 14 (25.9)
Erythema nod. Occurence
Before inclusion 95 (67.9) 38 (74.5) 133 (69.9)
After inclusion 45 (32.1) 13 (25.5) 58 (30.4)
Aphtous ulcers Occurence
Before inclusion 133 (55.9) 48 (62.3) 181 (57.5)
After inclusion 105 (44.1) 29 (37.7) 134 (42.5)
Skin EIM Occurence
Before inclusion 222 (62.7) 64 (69.1) 316 (64.5)
After inclusion 132 (37.3) 42 (30.9) 174 (35.5)
Age at Skin EIM Occurence (years)
median, IQR, range 39, 27–49, 11–73 39, 30–51, 18–79 39, 28–50,11–79
https://doi.org/10.1371/journal.pone.0210436.t001
IBD and skin manifestations
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Finally, we analysed the association of other EIM with the presence of skin manifestations.
We found significant associations of early skin manifestations with arthritis (74.6% vs. 41.9%,
p =<0.001), uveitis or iritis (24.9% vs. 7.9%, p =<0.001), ankylosing spondylitis (11.6% vs.
5.7%, p = <0.001) and EIM in general (77.4% vs. 42.3%, p =<0.001). These details are shown
in Table 3.
Relation between treatment and skin manifestations in CD patients
We analysed data for treatment history and the onset of skin manifestation. We found a signif-
icant difference between the two groups. Patients with skin EIM used significantly more often
antibiotics (24.6% vs. 16.3%, p = <0.001), steroids (91% vs. 85%, p = 0.003), immunomodula-
tors (88.4% vs. 79.7%, p =<0.001) and anti-TNF antibodies (77.4% vs. 59.2%, p =<0.001),
than patients without skin EIM. Furthermore, no differences for treatment with 5- ASA
(60.7% vs. 56.9%) and calcineurin inhibitors (2.8% vs. 1.7%) was detected (Tables 4 and 5).
Disease characteristics, complications and skin manifestations in UC/
IBDU patients
Patients with UC and skin EIM were more often female (58.1% vs. 45%, p = 0.004) and also
younger at the time of UC/IBDU diagnosis than UC patients without skin EIM (27 years vs. 31
years, p = 0.008). At the latest follow-up both groups were of comparable age (45 years vs. 46
years). Therefore, the observed disease duration in patients with skin manifestations was sig-
nificantly longer than in the other group without skin manifestations (13 years vs. 11 years,
p = 0.029). We found no difference between the two groups for BMI, smoking status or family
history of IBD. However, a considerable fraction of patients tended to stop smoking during
Table 2. Skin manifestations (pyoderma gangrenosum, erythema nodosum, aphthous ulcers) in relations to significant patient characteristics in epidemiology.
No Skin EIM Skin EIM All CD patients pvalue
Number of patients 1486 (80.8) 354 (19.2) 1840 (100.0)
Gender
Male 765 (51.5) 112 (31.6) 877 (47.7) <0.001
Female 721 (4805) 242 (68.4) 963 (52.3)
Age at diagnosis [y] (median,IQR) 27, 20–37, 3–81 25.8, 19–35, 1–74 26, 20–37, 1–81 0.006
Age at latest follow-up [y]
(median, IQR)
44, 33–57, 16–94 43, 32–54, 18–78 44, 33–56, 16–94 0.171
Disease duration [y] (median, IQR) 13, 7–21, 0–57 13, 8–22, 0–47 13, 7–21, 0–57 0.13
BMI at latest follow-up [kg/m2] (median, IQR) 23, 20–26, 14–47 22, 21–25, 15–31 23, 20–26, 14–47 0.408
Smoking status at diagnosis
Non-smoker 719 (48.4) 156 (52.5) 905 (49.2)
Smoker 695 (46.8) 159 (44.9) 854 (46.4)
Unknown 72 (4.9) 9 (2.5) 81 (4.4) 0.097
Smoking status at latest follow up
Non-Smoker 1007 (67.8) 237 (67.0) 1244 (67.6)
Smoker 469 (31.6) 114 (32.2) 583 (31.7)
Unknown 10 (0.7) 3 (0.8) 13 (0.7) 0.832
Family history of IBD
None 1129 (76.0) 270(76.3) 1399 (76.0)
Yes 186 (12.5) 60 (16.9) 246 (13.4)
Unknown 171 (11.5) 24 (6.8) 195 (10.6) 0.006
https://doi.org/10.1371/journal.pone.0210436.t002
IBD and skin manifestations
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follow-up (300 smokers at diagnosis vs. 198 smokers at latest follow-up). Data are presented in
Table 6.
Initially most patients, independent from skin manifestations, had either a pancolitis
(39.7% vs. 37.3%) or left- sided colitis (31.6% vs. 32.3%). The extent of the disease remained
stable during the disease course. However, patients with skin EIM suffered from higher disease
activity according to the MTWAI at enrolment (MTWAI 3 vs. 2, p =<0.001). IBD-related sur-
gery as a result of several other complications was significantly more frequent in patients with
skin EIM (18.4% vs. 10.2%, p = 0.003). Anemia was significantly more often observed in
patients with skin EIM during any SIBDCS follow-up visit (42.6% vs. 29.7%, p = 0.002), but
Table 3. Skin manifestations (pyoderma gangrenosum, erythema nodosum, aphthous ulcers) in relations to significant disease characteristics and complications in
CD patients.
No Skin EIM Skin EIM All CD patients pvalue
Number of patients 1486 (80.8) 354 (19.2) 1840 (100.0)
Initial disease location
L1 367 (24.7) 74 (20.9) 441 (24.0)
L2 279 (18.8) 86 (24.3) 365 (19.8)
L3 667 (44.9) 151 (42.7) 818 (44.5)
L4 only 11 (0.7) 3 (0.9) 14 (0.8)
Unclear/Unknown 162 (10.9) 40 (11.3) 202 (11.0) 0.156
Last disease location
L1 424 (28.5) 94 (26.6) 518 (28.2)
L2 442 (29.7) 114 (32.2) 556 (30.2)
L3 409 (27.5) 87 (24.6) 496 (27.0)
L4 only 30 (2.0) 16 (4.5) 46 (2.5)
Unclear/Unknown 181 (12.2) 43 (12.2) 224 (12.2) 0.06
CDAI at enrolment (median, IQR) 31, 11–49, 0–323 51, 20–96, 0–450 34, 12–76, 0–450 <0.001
CDAI at latest follow-up (median, IQR) 20, 6–47, 0–235 33, 8–65, 0–345 23, 6–50, 0–345 <0.001
CD-related complications
Perianal Fistula 372 (25.0) 108 (29.7) 477 (25.9) 0.074
Other Fistula 233 (15.7) 61 (17.2) 294 (16.0) 0.474
Any Fistula 207 (34.1) 132 (37.3) 639 (34.7) 0.26
Abscess 351 (23.6) 102 (28.8) 453 (24.6) 0.042
Stenosis 638 (42.9) 1545 (43.8) 793 (43.1) 0.771
CD-related surgery
Intestinal resection 608 (40.9) 152 (42.9) 760 (41.3) 0.487
Fistula/Abscess surgery 368 (24.8) 92 (26.0) 460 (25.0) 0.633
Any Surgery 758 (51.0) 184 (52.0) 942 (51.2) 0.743
Anemia
During SIBDCS follow-up 421 (28.9) 125 (35.5) 546 (30.2) 0.016
At latest follow-up 142 (11.9) 30 (10.5) 172 (11.6) 0.506
Vit. B12 level at latest follow-up [pmo]/l) (median, IQR) 241, 176–323, 33–2435 252, 188–354, 28–1319 243, 178–328, 28–2435 0.164
Ever received Vit. B12 Suppl. 595 (49.8) 173 (56.0) 768 (51.1) 0.052
Extraintestinal manifestations
Arthritis 622 (41.9) 264 (74.6) 886 (48.2) <0.001
Uveitis/Iritis 117 (7.9) 88 (24.9) 205 (11.1) <0.001
Ankylosing spondylitis 85 (5.7) 41 (11.6) 126 (6.8) <0.001
PSC 10 (0.7) 2 (0.6) 12 (0.7) 1
Any of the above 673 (42.3) 274 (77.4) 947 (51.5) <0.001
https://doi.org/10.1371/journal.pone.0210436.t003
IBD and skin manifestations
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not at latest follow- up (15.8% vs. 13.8%, p = 0.573). Vitamin B12 levels did not differ between
the two groups (285 pmol/l vs. 290 pmol/l), but those patients with skin EIM received signifi-
cantly more often vitamin B12 supplementation (31.5% vs. 21.7%, p = 0.015).
Finally, skin manifestations were significantly more often associated with other EIM (75.7%
vs 35.8%, p =<0.001) such as arthritis as the most frequent (68.4% vs. 30.3%, p =<0.001), uve-
itis/ iritis (16.2% vs. 4.5%, p =<0.001) and ankylosing spondylitis (7.4% vs. 2.5%, p = 0.001).
No such association could be detected for PSC (5.9% vs. 4.2%, p = 0.356). Data are presented
in Table 7.
Relation between treatment and skin manifestations in UC/IBDU patients
Looking at the treatment history of the compared groups, we discovered significantly more
frequently a therapy with antibiotics (17.6% vs. 9.6%, p = 0.003), steroids (92.6% vs. 77.8%, p =
<0.001), immunomodulators (75% vs. 59.5%, p =<0.001), anti-TNF antibodies (43.4% vs.
33.2%, p = 0.017) and calcineurin inhibitors (17.6% vs. 8.7%, p = 0.001) at enrolment in
patients with skin EIM. No difference was found for the therapy with 5- ASA (95% vs. 95%,
p = 0.956). Data are shown in Tables 8 and 9.
Table 4. Skin manifestations (pyoderma gangrenosum, erythema nodosum, aphthous ulcers) in relations to significant selected medication in Crohn’s patient;
5-ASA: Salazopyrin, EIM: extraintestinal manifestations.
No Skin EIM Skin EIM All CD patients pvalue
Number of patients 1486 (80.8) 354 (19.2) 1840 (100.0)
Treatment history
5-ASA 845 (56.9) 215 (60.7) 1060 (57.6) 0.185
Antibiotics 242 (16.3) 87 (24.6) 329 (17.9) <0.001
Steroids 1263 (85.0) 322 (91.0) 1585 (86.1) 0.003
Immunomodulators 1185 (79.7) 313 (88.4) 1498 (81.4) <0.001
Anti-TNF 879 (59.2) 274 (77.4) 1153 (62.7) <0.001
Cacineurin inhibitors 26 (1.7) 10 (2.8) 36 (2.0) 0.189
https://doi.org/10.1371/journal.pone.0210436.t004
Table 5. Multivariate logistic regression results for CD patients.
Outcome: Skin EIM OR (95%CI) pvalue
Gender
Male (ref) 1 (ref)
Female 1.701 (1.173–2.468) 0.005
Age at diagnosis [per year] 0.981 (0.966–0.995) 0.009
CDAI at latest follow-up [per CDAI point] 1.005 (1.001–1.008) 0.006
Immunomodulator treatment
Never (ref) 1 (ref)
Yes 2.123 (1.035–4.358) 0.04
Anti-TNF treatment
Never (ref) 1 (ref)
Yes 1.762 (1.146–2.708) 0.01
Other EIM
No (ref) 1 (ref)
Yes 4.452 (2.813–7.046) <0.001
https://doi.org/10.1371/journal.pone.0210436.t005
IBD and skin manifestations
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Longitudinal data considering the onset of cutaneous EIM in CD and UC/
IBDU patients
Finally, we assessed the longitudinal appearance of skin manifestation compared to both, other
EIMs and first diagnosis of IBD (Fig 1). We found, that skin manifestations in either CD and
UC/IBDU patients were the most frequent EIM of the disease. They were mainly reported as
first EIM (75.5% vs. 87%) rather than as subsequent EIM (24.5% vs. 13.0%). After all, 23.6% of
the skin manifestations in all IBD patients occur even before the diagnosis of the intestinal dis-
ease. This occurs slightly more often in CD patients than in UC patients (28.6% vs. 13%).
Discussion
The aim of our study was to identify epidemiological and clinical factors being associated with
the development of skin manifestations in patients with IBD. Our results revealed a higher
prevalence of skin manifestations overall in female and young patients independent from the
IBD subtype. This gender association has not been demonstrated for cutaneous EIM in general
so far, although it was known from former studies, that especially erythema nodosum is associ-
ated predominantly with female gender [2, 11, 24, 26]. Further, a female predominance was
generally known for familial IBD [27]. This might be due to some x-linked genes that are asso-
ciated with autoimmune or chronic inflammatory diseases. For IBD there was so far only one
such gene known called ARHGEF6 [22, 28]. For patients with CD, a family history of IBD was
also highly associated with skin manifestations, while no such associations were detected for
patients with UC. These results were inconsistent with those from former studies where no
Table 6. Skin manifestations (pyoderma gangrenosum, erythema nodosum, aphthous ulcers) in relation to signif-
icant patient characteristics in epidemiology.
No Skin EIM Skin EIM All UC/IBDU pat. pvalue
Number of patients 1290 (90.5) 136 (9.5) 1426 (100.0)
Gender
Male 709 (55.0) 57 (41.9) 766 (53.7)
Female 581 (45.0) 79 (58.1) 660 (46.3) 0.004
Age at diagnosis [y]
(median, IQR)
31, 23–41, 3–83 27, 21–38, 14–79 31, 23–41, 3–83 0.008
Age at latest follow-up [y]
(median, IQR)
46, 36–57, 17–89 45, 35–56, 18–86 46, 36–57, 17–89 0.409
Disease duration [y]
(median, IQR)
11, 6–18, 0–59 13, 8–22, 0–41 11, 6–18, 0–59 0.029
BMI at latest follow-up [kg/m2]
(median, IQR)
24, 21–26, 18–37 27, 21–28, 21–31 24, 21–27, 18–37 0.49
Smoking status at diagnosis
Non-smoker 966 (74.9) 106 (77.9) 1072 (75.2)
Smoker 272 (21.1) 28 (20.6) 300 (21.0)
Unknown 52 (4.0) 2 (1.2) 54 (3.8) 0.349
Smoking status at latest follow up
Non-Smoker 1091 (84.6) 117 (86.0) 1208 (84.7)
Smoker 180 (14.0) 18 (13.2) 198 (13.9)
Unknown 19 (1.5) 1 (0.7) 20 (1.4) 0.912
Family history of IBD
None 1020 (79.1) 106 (77.9) 1126 (79.0)
Yes 131 (10.2) 20 (14.7) 151 (10.6)
Unknown 139 (10.8) 10 (7.4) 149 (10.4.) 0.149
https://doi.org/10.1371/journal.pone.0210436.t006
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significant association of skin manifestations and family history could be observed for either
UC or CD [26].
Our study demonstrated that IBD patients with skin EIM are in general younger at time of
IBD diagnosis than IBD patients without skin EIM during their disease course. The onset of
skin manifestations as well as a younger age at disease onset were both factors pointing
towards a more severe disease course [29]. However, it must be pointed out that a younger age
Table 7. Skin manifestations (pyoderma gangrenosum, erythema nodosum, aphthous ulcers) in relations to significant disease characteristics and complications in
patients with ulcerative colitis (UC)/ IBD unclassified (IBDU).
No Skin EIM Skin EIM All UC/IBDU pat. pvalue
Number of patients 1290 (90.5) 136 (9.5) 1426 (100.0)
Initial disease location
Pancolitis 481 (37.3) 54 (39.7) 535 (37.5)
Left-sided colitis 416 (32.3) 43 (31.6) 459 (32.2)
Proctitis 262 (20.3) 18 (13.2) 280(19.6)
Unclear/Unknown 131 (10.2) 21 (15.4) 152 (10.7) 0.087
Last disease location
Pancolitis 450 (34.9) 44 (32.4) 494 (34.6)
Left-sided colitis 462 (35.8) 53 (39.0) 515 (36.1)
Proctitis 230 (17.8) 21 (15.4) 251 (17.6)
Unclear/Unknown 148 (11.5) 18 (13.2) 166 (11.6) 0.731
MTWAI at enrolment
(median, IQR)
2, 1–5, 0–19 3, 2–7, 0–18 2, 1–5, 0–19 <0.001
MTWAI at latest follow-up
(median, IQR)
2, 0–4, 0–18 2, 1–4, 0–18 2, 0–4, 0–18 0.015
IBD-related surgery 131 (10.2) 25 (18.4) 156 (10.9) 0.003
Anemia
During SIBDCS follow-up 354 (29.7) 58 (42.6) 412 (31.0) 0.002
at latest follow-up 122 (13.8) 16 (15.8) 138 (14.0) 0.573
Vit. B12 level at latest follow-up [pmol/l] (median,IQR) 290, 215–379, 24–1696 285, 213–351, 41–1476 290, 215–374, 24–1696 0.584
Ever received Vit. B12 Suppl. 210 (21.7) 39 (31.5) 249 (22.8) 0.015
Extraintestinal manifestations
Arthritis 391 (30.3) 93 (68.4) 484 (33.9) <0.001
Uveitis/Iritis 58 (4.5) 22 (16.2) 80 (5.6) <0.001
Ankylosing Spondylitis 32 (2.5) 10 (7.4) 42 (2.9) 0.001
PSC 54 (4.2) 8 (5.9) 62 (4.3) 0.356
Any of the above 462 (35.8) 103 (75.7) 565 (39.6) <0.001
https://doi.org/10.1371/journal.pone.0210436.t007
Table 8. Skin manifestations (pyoderma gangrenosum, erythema nosodusm, aphthous ulcers) in relations to significant selected medication in patient with UC/
IBDU.
No Skin EIM Skin EIM All UC/IBDU pat. pvalue
Number of patients 1290 (90.5) 136 (9.5) 1426 (100.0)
Treatment history
5-ASA 1225 (95.0) 129 (95.0) 1354 (95.0) 0.956
Antibiotics 124 (9.6) 24 (17.6) 148 (10.4) 0.003
Steroids 1004 (77.8) 126 (92.6) 1130 (79.2) <0.001
Immunomodulators 768 (59.5) 102 (75.0) 870 (61.0) <0.001
Anti-TNF 428 (33.2) 59 (43.4) 487 (34.2) 0.017
Calcineurin inhibitors 112 (8.7) 24 (17.6) 136 (9.5) 0.001
https://doi.org/10.1371/journal.pone.0210436.t008
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at diagnosis of patients with skin EIM (those patients are about 26 to 27 years at diagnosis) is
not related to early onset IBD in pediatric patients. Smoking had also been associated with a
severe disease course in CD patients, but with a milder course of disease in UC patients [30].
In CD, several studies showed more frequent relapses with higher use of steroids, immuno-
modulators and biologicals, as well as a higher rate of hospitalizations in smokers [31–34].
Compared to non-smokers, the risk of developing CD is increased fivefold in women and 1.3
fold in men [35]. However, smoking did not affect the onset of skin manifestations in CD or
UC patients.
Erythema nodosum as well as aphthous ulcers had been correlated with intestinal disease
activity in previous studies [36, 37]. Those observations point into the same direction as our
data, since the patients with any of the three skin EIM (erythema nodosum, pyoderma gangre-
nosum and aphthous ulcers) revealed higher CDAI in CD and MTWAI in UC patients with
skin manifestations in the SIBDC. These results were consistent with earlier studies showing
that 70% of the patients with EIM presented with extensive intestinal disease, while patients
without EIM present with a high intestinal disease activity in only 28% of the cases [10, 15, 38].
Severe intestinal disease can even be a predisposing factor for the onset of pyoderma gangreno-
sum [9, 38], regarding CD it favors the onset of erythema nodosum [39] and in the case of
aphthous ulcers the connection to intestine is obviously given by anatomy. Therefore, the ther-
apy of intestinal disease remains the primary therapy of the majority of cutaneous manifesta-
tions. Consequently, it is of high importance to treat the intestinal disease as early as possible
and with high efficiency [13, 29, 40]. As in former studies, we found, that skin manifestations
were in almost a quarter of the cases even reported before the diagnosis of the intestinal disease
[14]. Their appearance should therefore be taken into account for daily clinical practice and
patient care.
A limitation of the SIBDCS, however, is the fact that it is not fully population based as two
third of SIBDCS patients are treated at tertiary center hospitals. Consequently, the study popu-
lation consists of a large number of patients with a severe disease course, who are more likely
to develop EIM. Nevertheless, the UC and CD patients with skin EIM in our study needed
more antibiotic therapy, steroids, immunomodulators, anti-TNF antibodies and calcineurin
inhibitors (UC patients only) than patients without skin EIM. This supported the observation
that patients with EIM suffered often from a more severe disease course than patients without
EIM (presence of EIM is a marker for a severe disease course itself). A further limitation of our
study is that, due to the design of our study, we cannot identify a single skin manifestation that
is driving the observed associations. Due our study design, we are only able to present associa-
tions between the onset of skin manifestations at any time during disease course and certain
epidemiological or medical conditions. However, we are not able to provide risk factor analysis
for the onset of skin EIM in our cohort. Such a risk factor analysis would be required to pro-
vide information about a possible, specific driver skin EIM in the patients. Also due to the
Table 9. Multivariate logistic regression results for UC/IBDU patients.
Outcome: Skin EIM OR (95%CI) pvalue
Gender
Male (ref) 1 (ref)
Female 1587 (1.018–2.474) 0.041
Age at diagnosis [per year] 0.974 (0.956–0.993) 0.006
Other EIM
No (ref) 1 (ref)
Yes 4.048 (2.511–6.526) <0.001
https://doi.org/10.1371/journal.pone.0210436.t009
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design of our study and the SIBDCS, we are not able to provide sufficient information on treat-
ment response of the skin manifestations or whether IBD treatment was changed based on the
presentation of these skin manifestations.
Although according to our data it was difficult to verify, whether the increased use of bio-
logics was due to the intestinal disease activity or the skin manifestation itself. For patients
with UC and treated with the basic therapy 5–ASA, no difference between presence and
absence of skin manifestations was found. This observation further indicated that skin mani-
festations occurred in patients with more severe disease. Interestingly and in good accordance
to the above-mentioned findings, we detected a higher frequency of abscesses in CD patients
in the group with skin manifestations. Although it must be mentioned that this higher fre-
quency of abscesses did not result in a more frequent abscess surgery, the onset of abscesses
alone can be already regarded as a marker for a severe CD disease course. We observed a
higher rate of anemia in patients with skin manifestations in either CD or UC. These patients
were substituted with vitamin B12 more often, although they had no vitamin B12 deficiency.
In the course, anemia was no longer more frequent in patients with skin manifestations. We
suggest that this was due to improved resorption of substrates after the resolution of intestinal
inflammation through successful therapy.
Fig 1. Cumulative proportion of skin manifestations over the years in Crohn’s patient (CD) and in patient with Ulcerative Colitis (UC)/ IBD
unclassified (IBDU).
https://doi.org/10.1371/journal.pone.0210436.g001
IBD and skin manifestations
PLOS ONE | https://doi.org/10.1371/journal.pone.0210436 January 25, 2019 12 / 16
We identified female gender and early onset of disease in UC and CD as well as a positive
family history for skin manifestations in CD as epidemiological factors being associated with
the development of skin manifestations in IBD patients. In the case of already known IBD,
especially young female patients with high disease activity had a high probability also to
develop skin manifestations. Our findings correlate with those from Ampuero et al in 2014
where female gender, young age at diagnosis, Crohn’s disease and the presence of other EIM
were also identified as risk factors for skin manifestations in IBD. On the other hand they had
shown that if biologicals were used early in the course of disease it prevented the development
of skin manifestations [26]. For patients with such a constellation, special care should therefore
be taken to detect the appearance of skin lesions as early as possible and to optimize patient
care.
In summary, our data demonstrate that erythema nodosum, pyoderma gangrenosum, and
aphthous ulcers in IBD patients are associated with a more severe disease phenotype. Further
research will be needed to clarify the potential pathogenetic impact on the development of
skin EIMs. This knowledge would be most helpful in the diagnosis and treatment of IBD
patients and might help to stratify the patients according to their risk for developing skin man-
ifestations and to initiate appropriate treatment.
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